Iodine-131-MIP-1095 | THE "NEW" PROSTATE CANCER INFOLINK

Follow The "New" Prostate Cancer InfoLink news blog on TWITTER or FACEBOOK.
The "New" Prostate Cancer InfoLink has been developed to become a primary source of accurate, current, and topical information about prostate cancer for patients and their families.
A service of

Prostate Cancer International.
Awards
Other PCI web sites

El Cáncer de Próstata Latinoamérica
Prostate Cancer Africa
Prostate Cancer Caribbean
Solidarité Prostate InfoLink
Copyright © 2008-18 Prostate Cancer International, Inc.

I-131-MIP-1095 to enter randomized, Phase II clinical trial

Posted on October 13, 2018 by Sitemaster

As we reported last year, a new radiopharmaceutical has entered the pack. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, injectable, Iodine-131-MIP-1095, metastatic, radiation, systenic, therapy | 3 Comments »

Iodine-131-MIP-1095, a new radiopharmaceutical, in clinical trials at MSKCC

Posted on January 27, 2017 by Sitemaster

There are few radiopharmaceuticals in clinical trials in the US (although there are several in use in Germany), so when a new one is announced, we take notice. … READ MORE …

Filed under: Drugs in development | Tagged: Iodine-131-MIP-1095, radiopharmaceutical, Treatment | 9 Comments »

THE "NEW" PROSTATE CANCER INFOLINK

A service of

Awards

Other PCI web sites

I-131-MIP-1095 to enter randomized, Phase II clinical trial

Iodine-131-MIP-1095, a new radiopharmaceutical, in clinical trials at MSKCC

Disclaimer

Hot Posts …

… and Archives